HHS And Pfizer Reach Agreement To Increase Patient Access To Paxlovid; Will Begin Preparations For Pfizer To Transition Paxlovid To The Commercial Market In November 2023; Up-to-date Product Will Be Refreshed From Pfizer Through 2028
Portfolio Pulse from Benzinga Newsdesk
The Department of Health and Human Services (HHS) and Pfizer have reached an agreement to increase patient access to Paxlovid. Pfizer will transition Paxlovid to the commercial market in November 2023 and will continue to refresh the product through 2028.
October 13, 2023 | 8:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's agreement with HHS to increase access to Paxlovid and transition it to the commercial market in November 2023 could potentially boost Pfizer's revenues and stock price.
The agreement with HHS will increase the accessibility of Paxlovid, potentially leading to increased sales and revenues for Pfizer. The transition of Paxlovid to the commercial market in November 2023 will open up a new revenue stream for Pfizer, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100